| Advances in the early detection of hepatobiliary cancers HÇ Yıldırım, G Kavgaci, E Chalabiyev, O Dizdar Cancers 15 (15), 3880, 2023 | 6 | 2023 |
| The burden of polypharmacy and drug–drug interactions in older cancer patients treated with immunotherapy DC Guven, G Kavgaci, OH Aktepe, HC Yildirim, TK Sahin, S Aksoy, ... Journal of Oncology Pharmacy Practice 28 (4), 785-793, 2022 | 5 | 2022 |
| The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors DC Guven, OH Aktepe, MS Aksun, TK Sahin, G Kavgaci, E Ucgul, IY Cakir, ... Cancer Biomarkers 34 (2), 189-199, 2022 | 4 | 2022 |
| The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors DC Guven, DA Ozbek, TK Sahin, G Kavgaci, MS Aksun, E Erul, ... Anti-Cancer Drugs 34 (6), 783-790, 2023 | 3 | 2023 |
| Prognostic factors associated with locally advanced gastric cancer in patients treated with adjuvant chemotherapy H YILDIRIM, D Güven, E Chalabiyev, H Taban, F YILMAZ, S YAŞAR, ... Journal of Oncological Science 8 (3), 2022 | 2 | 2022 |
| MO368 THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY DC Güven, DA Ozbek, TK Sahin, MS Aksun, G Kavgaci, C Cebrayilov, ... Nephrology Dialysis Transplantation 36 (Supplement_1), gfab082. 0022, 2021 | 2 | 2021 |
| Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer G Kavgaci, O Dizdar, S Yalcin Anti-cancer drugs 35 (5), 459-461, 2024 | 1 | 2024 |
| The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review DC Guven, G Kavgaci, E Erul, MP Syed, T Magge, A Saeed, S Yalcin, ... The Oncologist 29 (5), e580-e600, 2024 | 1 | 2024 |
| Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors G Kavgaci, DC Guven, Y Kaygusuz, E Karaca, O Dizdar, S Kilickap, ... Supportive Care in Cancer 32 (7), 1-7, 2024 | | 2024 |
| Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine TK Sahin, A Akyildiz, OT Dogan, G Kavgaci, DC Guven, S Aksoy Pharmaceuticals 17 (7), 824, 2024 | | 2024 |
| Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on … HC Yildirim, C Kapar, B Koksal, M Seyyar, PC Sanci, M Guliyev, P Perkin, ... Journal of Chemotherapy, 1-7, 2024 | | 2024 |
| Acute heart failure following pazopanib treatment: a literature review featuring two case reports N Kertmen, G Kavgaci, HC Yildirim, O Dizdar Anti-Cancer Drugs 35 (3), 302-304, 2024 | | 2024 |
| Implementation of clinical pharmacy practices in nephrology unit K Tecen, M ÜZERK KİBAR, G KAVGACI, S Bayraktar-Ekincioglu, ... INTERNATIONAL JOURNAL OF CLINICAL PHARMACY 40 (1), 2018 | | 2018 |
| Implementation of clinical pharmacy practices in nephrology unit K TECEN YÜCEL, M ÜZERK KİBAR, G KAVGACI, A Ekincioğlu, ... | | |
